2334 related articles for article (PubMed ID: 12122208)
1. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
4. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
5. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
6. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
Park SS; Lee D
Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
[TBL] [Abstract][Full Text] [Related]
7. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
8. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
9. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
10. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
13. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
14. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
15. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors.
Krenz A; Falkenburger BH; Gerhardt E; Drinkut A; Schulz JB
J Neurochem; 2009 Jan; 108(1):139-46. PubMed ID: 19094062
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
17. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
18. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
19. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
